This information is disclosed in accordance with the Securities Markets Act and NASDAQ OMX Stockholm's rules regarding public offers on the stock market.
This press release may not be distributed, directly or indirectly, in or into, Australia, Canada, Japan, New Zealand, South Africa, Switzerland or the United States of America. The Offer is not being made to (and acceptances will not be accepted from) persons in those countries or in any other country where the making of the Offer, the distribution of this press release or acceptance of the Offer requires further offer documents, filings or other measures in addition to those required by Swedish law.
Ratos has today announced the offer document regarding the offer to the shareholders and convertible debenture holders of Biolin Scientific to tender all their outstanding shares and convertible debentures in Biolin Scientific to Ratos. The offer document is available in a Swedish language version only.
The offer document will be mailed to all directly registered shareholders and convertible debenture holders of Biolin Scientific and can be ordered from ABG Sundal Collier, +46 8 566 286 00. The offer document will also be available at Ratos's office, Drottninggatan 2, 111 96 Stockholm, Sweden, at ABG Sundal Collier's office, Regeringsgatan 65, 5tr, 103 89 Stockholm, Sweden, as well as at Remium's office, Kungsgatan 12-14, 111 35 Stockholm, Sweden. The offer document is also available on www.ratos.se, www.abgsc.se and www.remium.se.
The acceptance period for the offer is expected to commence on 1 December 2010 and end on 21 December 2010.
Stockholm, 30 November 2010
The Board of Directors
For further information, please contact:
Arne Karlsson, CEO, +46 8 700 17 00
Emma Rheborg, Head of Corporate Communications & IR, +46 8 700 17 20